Cargando…
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
BACKGROUND: Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood. METHODS: For a comprehensive analysis...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962046/ https://www.ncbi.nlm.nih.gov/pubmed/35346322 http://dx.doi.org/10.1186/s13045-022-01253-z |
_version_ | 1784677714172575744 |
---|---|
author | Xia, Tao Li, Keyu Niu, Nan Shao, Yingkuan Ding, Ding Thomas, Dwayne L. Jing, Hao Fujiwara, Kenji Hu, Haijie Osipov, Arsen Yuan, Chunhui Wolfgang, Christopher L. Thompson, Elizabeth D. Anders, Robert A. He, Jin Mou, Yiping Murphy, Adrian G. Zheng, Lei |
author_facet | Xia, Tao Li, Keyu Niu, Nan Shao, Yingkuan Ding, Ding Thomas, Dwayne L. Jing, Hao Fujiwara, Kenji Hu, Haijie Osipov, Arsen Yuan, Chunhui Wolfgang, Christopher L. Thompson, Elizabeth D. Anders, Robert A. He, Jin Mou, Yiping Murphy, Adrian G. Zheng, Lei |
author_sort | Xia, Tao |
collection | PubMed |
description | BACKGROUND: Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood. METHODS: For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data. RESULTS: This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B(+)CD8(+) effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1(−)EOMES(−)CD8(+) effector T cells are associated with long-term survival. However, only the density of PD-1(−)EOMES(−)CD8(+) T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1(+) tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1(+) M1 or M2, PD-L1(−) M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1(−) M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1(+) tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion. CONCLUSIONS: This study suggests that the densities of Granzyme-B(+)CD8(+) effector T cells and non-exhausted PD-1(−)EOMES(−)CD8(+) T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1(+) tumor-associated macrophages as the immunotherapy for cholangiocarcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01253-z. |
format | Online Article Text |
id | pubmed-8962046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89620462022-03-30 Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses Xia, Tao Li, Keyu Niu, Nan Shao, Yingkuan Ding, Ding Thomas, Dwayne L. Jing, Hao Fujiwara, Kenji Hu, Haijie Osipov, Arsen Yuan, Chunhui Wolfgang, Christopher L. Thompson, Elizabeth D. Anders, Robert A. He, Jin Mou, Yiping Murphy, Adrian G. Zheng, Lei J Hematol Oncol Research BACKGROUND: Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood. METHODS: For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data. RESULTS: This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B(+)CD8(+) effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1(−)EOMES(−)CD8(+) effector T cells are associated with long-term survival. However, only the density of PD-1(−)EOMES(−)CD8(+) T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1(+) tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1(+) M1 or M2, PD-L1(−) M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1(−) M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1(+) tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion. CONCLUSIONS: This study suggests that the densities of Granzyme-B(+)CD8(+) effector T cells and non-exhausted PD-1(−)EOMES(−)CD8(+) T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1(+) tumor-associated macrophages as the immunotherapy for cholangiocarcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01253-z. BioMed Central 2022-03-28 /pmc/articles/PMC8962046/ /pubmed/35346322 http://dx.doi.org/10.1186/s13045-022-01253-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Xia, Tao Li, Keyu Niu, Nan Shao, Yingkuan Ding, Ding Thomas, Dwayne L. Jing, Hao Fujiwara, Kenji Hu, Haijie Osipov, Arsen Yuan, Chunhui Wolfgang, Christopher L. Thompson, Elizabeth D. Anders, Robert A. He, Jin Mou, Yiping Murphy, Adrian G. Zheng, Lei Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses |
title | Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses |
title_full | Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses |
title_fullStr | Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses |
title_full_unstemmed | Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses |
title_short | Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses |
title_sort | immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962046/ https://www.ncbi.nlm.nih.gov/pubmed/35346322 http://dx.doi.org/10.1186/s13045-022-01253-z |
work_keys_str_mv | AT xiatao immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT likeyu immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT niunan immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT shaoyingkuan immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT dingding immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT thomasdwaynel immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT jinghao immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT fujiwarakenji immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT huhaijie immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT osipovarsen immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT yuanchunhui immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT wolfgangchristopherl immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT thompsonelizabethd immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT andersroberta immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT hejin immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT mouyiping immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT murphyadriang immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses AT zhenglei immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses |